Cargando…

Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer

BACKGROUND: Olaratumab is a platelet-derived growth factor receptor-α (PDGFRα)-targeting monoclonal antibody blocking PDGFRα signaling. PDGFRα expression is associated with a more aggressive phenotype and poor ovarian cancer outcomes. This randomized, open label phase II study evaluated olaratumab p...

Descripción completa

Detalles Bibliográficos
Autores principales: McGuire, William P., Penson, Richard T., Gore, Martin, Herraez, Antonio Casado, Peterson, Patrick, Shahir, Ashwin, Ilaria, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307114/
https://www.ncbi.nlm.nih.gov/pubmed/30591028
http://dx.doi.org/10.1186/s12885-018-5198-4
_version_ 1783382931434110976
author McGuire, William P.
Penson, Richard T.
Gore, Martin
Herraez, Antonio Casado
Peterson, Patrick
Shahir, Ashwin
Ilaria, Robert
author_facet McGuire, William P.
Penson, Richard T.
Gore, Martin
Herraez, Antonio Casado
Peterson, Patrick
Shahir, Ashwin
Ilaria, Robert
author_sort McGuire, William P.
collection PubMed
description BACKGROUND: Olaratumab is a platelet-derived growth factor receptor-α (PDGFRα)-targeting monoclonal antibody blocking PDGFRα signaling. PDGFRα expression is associated with a more aggressive phenotype and poor ovarian cancer outcomes. This randomized, open label phase II study evaluated olaratumab plus liposomal doxorubicin compared with liposomal doxorubicin alone in advanced ovarian cancer patients. METHODS: Patients with platinum-refractory or platinum-resistant advanced ovarian cancer were randomized 1:1 to receive liposomal doxorubicin (40 mg/m(2), intravenous infusion) administered every 4 weeks with or without olaratumab (20 mg/kg, IV infusion) every 2 weeks. Patients were stratified based on prior response to platinum therapy (refractory vs resistant). The primary efficacy endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate, duration of response, and safety. RESULTS: A total of 123 patients were treated (62 olaratumab+liposomal doxorubicin; 61 liposomal doxorubicin). Median PFS was 4.2 months for olaratumab+liposomal doxorubicin and 4.0 months for liposomal doxorubicin (stratified hazard ratio [HR] = 1.043; 95% confidence interval [CI] 0.698–1.558; p = 0.837). Median OS was 16.6 months and 16.2 months in the olaratumab+liposomal doxorubicin and liposomal doxorubicin arms, respectively (HR = 1.098; 95% CI 0.71–1.71). In the platinum-refractory subgroup, median PFS was 5.5 months (95% CI 1.6–9.2) and 3.7 months (95% CI 1.9–9.2) in the olaratumab+liposomal doxorubicin (n = 15) and liposomal doxorubicin arms (n = 16), respectively (HR = 0.85; 95% CI 0.38–1.91). Overall, 59.7% (olaratumab+liposomal doxorubicin) and 65.6% (liposomal doxorubicin) of patients reported grade ≥ 3 adverse events regardless of causality. The most common treatment-emergent adverse events (all grades) regardless of causality were fatigue related (61%), nausea (57%), and constipation (52%) with olaratumab+liposomal doxorubicin and nausea (64%), fatigue related (62%), and mucositis (46%) with liposomal doxorubicin. CONCLUSIONS: The addition of olaratumab to liposomal doxorubicin did not result in significant prolongation of PFS or OS in platinum-resistant or platinum-refractory ovarian cancer. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00913835; registered June 2, 2009.
format Online
Article
Text
id pubmed-6307114
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63071142019-01-02 Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer McGuire, William P. Penson, Richard T. Gore, Martin Herraez, Antonio Casado Peterson, Patrick Shahir, Ashwin Ilaria, Robert BMC Cancer Research Article BACKGROUND: Olaratumab is a platelet-derived growth factor receptor-α (PDGFRα)-targeting monoclonal antibody blocking PDGFRα signaling. PDGFRα expression is associated with a more aggressive phenotype and poor ovarian cancer outcomes. This randomized, open label phase II study evaluated olaratumab plus liposomal doxorubicin compared with liposomal doxorubicin alone in advanced ovarian cancer patients. METHODS: Patients with platinum-refractory or platinum-resistant advanced ovarian cancer were randomized 1:1 to receive liposomal doxorubicin (40 mg/m(2), intravenous infusion) administered every 4 weeks with or without olaratumab (20 mg/kg, IV infusion) every 2 weeks. Patients were stratified based on prior response to platinum therapy (refractory vs resistant). The primary efficacy endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate, duration of response, and safety. RESULTS: A total of 123 patients were treated (62 olaratumab+liposomal doxorubicin; 61 liposomal doxorubicin). Median PFS was 4.2 months for olaratumab+liposomal doxorubicin and 4.0 months for liposomal doxorubicin (stratified hazard ratio [HR] = 1.043; 95% confidence interval [CI] 0.698–1.558; p = 0.837). Median OS was 16.6 months and 16.2 months in the olaratumab+liposomal doxorubicin and liposomal doxorubicin arms, respectively (HR = 1.098; 95% CI 0.71–1.71). In the platinum-refractory subgroup, median PFS was 5.5 months (95% CI 1.6–9.2) and 3.7 months (95% CI 1.9–9.2) in the olaratumab+liposomal doxorubicin (n = 15) and liposomal doxorubicin arms (n = 16), respectively (HR = 0.85; 95% CI 0.38–1.91). Overall, 59.7% (olaratumab+liposomal doxorubicin) and 65.6% (liposomal doxorubicin) of patients reported grade ≥ 3 adverse events regardless of causality. The most common treatment-emergent adverse events (all grades) regardless of causality were fatigue related (61%), nausea (57%), and constipation (52%) with olaratumab+liposomal doxorubicin and nausea (64%), fatigue related (62%), and mucositis (46%) with liposomal doxorubicin. CONCLUSIONS: The addition of olaratumab to liposomal doxorubicin did not result in significant prolongation of PFS or OS in platinum-resistant or platinum-refractory ovarian cancer. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00913835; registered June 2, 2009. BioMed Central 2018-12-27 /pmc/articles/PMC6307114/ /pubmed/30591028 http://dx.doi.org/10.1186/s12885-018-5198-4 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
McGuire, William P.
Penson, Richard T.
Gore, Martin
Herraez, Antonio Casado
Peterson, Patrick
Shahir, Ashwin
Ilaria, Robert
Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
title Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
title_full Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
title_fullStr Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
title_full_unstemmed Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
title_short Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
title_sort randomized phase ii study of the pdgfrα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307114/
https://www.ncbi.nlm.nih.gov/pubmed/30591028
http://dx.doi.org/10.1186/s12885-018-5198-4
work_keys_str_mv AT mcguirewilliamp randomizedphaseiistudyofthepdgfraantibodyolaratumabplusliposomaldoxorubicinversusliposomaldoxorubicinaloneinpatientswithplatinumrefractoryorplatinumresistantadvancedovariancancer
AT pensonrichardt randomizedphaseiistudyofthepdgfraantibodyolaratumabplusliposomaldoxorubicinversusliposomaldoxorubicinaloneinpatientswithplatinumrefractoryorplatinumresistantadvancedovariancancer
AT goremartin randomizedphaseiistudyofthepdgfraantibodyolaratumabplusliposomaldoxorubicinversusliposomaldoxorubicinaloneinpatientswithplatinumrefractoryorplatinumresistantadvancedovariancancer
AT herraezantoniocasado randomizedphaseiistudyofthepdgfraantibodyolaratumabplusliposomaldoxorubicinversusliposomaldoxorubicinaloneinpatientswithplatinumrefractoryorplatinumresistantadvancedovariancancer
AT petersonpatrick randomizedphaseiistudyofthepdgfraantibodyolaratumabplusliposomaldoxorubicinversusliposomaldoxorubicinaloneinpatientswithplatinumrefractoryorplatinumresistantadvancedovariancancer
AT shahirashwin randomizedphaseiistudyofthepdgfraantibodyolaratumabplusliposomaldoxorubicinversusliposomaldoxorubicinaloneinpatientswithplatinumrefractoryorplatinumresistantadvancedovariancancer
AT ilariarobert randomizedphaseiistudyofthepdgfraantibodyolaratumabplusliposomaldoxorubicinversusliposomaldoxorubicinaloneinpatientswithplatinumrefractoryorplatinumresistantadvancedovariancancer